Gout is often poorly managed, with low rates of successful long-term urate lowering. A new 'package of care' intervention for treatment of patients with gout now offers ways to improve outcomes. The intervention, involving both a rheumatologist and gout nurse specialist, provides a framework for best practice in gout management.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Zhang, W. et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312–1324 (2006).
Solomon, D. H., Avorn, J., Levin, R. & Brookhart, M. A. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Ann. Rheum. Dis. 67, 609–613 (2008).
Roddy, E., Zhang, W. & Doherty, M. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann. Rheum. Dis. 66, 1311–1315 (2007).
Dalbeth, N., Kumar, S., Stamp, L. & Gow, P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J. Rheumatol. 33, 1646–1650 (2006).
Reach, G. Treatment adherence in patients with gout. Joint Bone Spine 78, 456–459 (2011).
Rees, F., Jenkins, W. & Doherty, M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2012-201676.
Hande, K. R., Noone, R. M. & Stone, W. J. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am. J. Med. 76, 47–56 (1984).
Stamp, L. K. et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 63, 412–421 (2011).
Zhu, Y., Pandya, B. J. & Choi, H. K. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 63, 3136–3141 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
N. Dalbeth declares that she has acted as a consultant for Ardea Biosciences, Fonterra, Metabolex, Novartis and Takeda. She has received Speakers' honoraria from Novartis, and grant/research support from Fonterra and Novartis. She is a patent holder or applicant for Fonterra.
Rights and permissions
About this article
Cite this article
Dalbeth, N. A new 'package of care' strategy for effective gout management. Nat Rev Rheumatol 8, 507–508 (2012). https://doi.org/10.1038/nrrheum.2012.129
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.129
